Sanofi, Regeneron score their 7th indication for Dupixent with FDA nod to treat hives condition
Sanofi and Regeneron have scored an FDA approval for Dupixent in its seventh indication—chronic spontaneous urticaria (CSU). The nod comes 18 months after the U.S. regulator rejected Dupixent in the same indication.
Sanofi and Regeneron have scored an FDA approval for Dupixent in its seventh indication—chronic spontaneous urticaria (CSU). The nod comes 18 months after the U.S. regulator rejected Dupixent in the same indication.
